Use of the basic form of recombinant human erythropoietin in the treatment of patients with spinocerebellar ataxia with CAG repeat mutations

摘要

The present invention relates to the use of pharmaceutical compositions containing the basic form of recombinant human erythropoietin (rhEPO) as an active ingredient, which are administered via the nasal route, in the treatment of spinocerebellar ataxia (SCA) with CAG repeat mutations, particularly type 2 SCA. The invention also relates to a method for classifying patients as responsive or unresponsive to treatment with the basic form of rhEPO.